Sopilcin 20 Mg/10 Ml & 50 Mg/25 Ml 20 mg/10 ml & 50 mg/25 ml Concentrate for infusion
PDF Leaflet Revision Date: 09 December 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic breast cancer, advanced ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma.
Dosage (summary)
50 mg/mu00b2 every 4 weeks for breast/ovarian cancer; 30 mg/mu00b2 on day 4 of bortezomib regimen for multiple myeloma; 20 mg/mu00b2 every 2-3 weeks for AIDS-KS.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic effects possible.
Key Drug Interactions
- Caution with other cytotoxic agents
- May enhance hepatotoxicity of 6-mercaptopurine
Contraindications
- Hypersensitivity to doxorubicin
- Pregnancy
- Breastfeeding
- AIDS-KS treatable with local therapy
Common side effects
- Palmar-plantar erythrodysesthesia
- Nausea
- Stomatitis
- Myelosuppression
Counselling Points
- Avoid pregnancy during treatment
- Monitor for infusion reactions
- Report any signs of cardiac issues
Serious warnings
- Cardiac monitoring required
- Risk of secondary malignancies
- Infusion reactions possible
Important Disclaimer
The Sopilcin 20 Mg/10 Ml & 50 Mg/25 Ml 20 mg/10 ml & 50 mg/25 ml Concentrate for infusion professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
